Penumbra (PEN) Competitors

Penumbra (NYSE:PEN) and Globus Medical (NYSE:GMED) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.

Is PEN or GMED more profitable?

Penumbra has a net margin of 8.59% compared to Globus Medical's net margin of 7.83%. Globus Medical's return on equity of 8.82% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	8.59%	7.49%	5.60%
Globus Medical	7.83%	8.82%	7.20%

Do analysts rate PEN or GMED?

Penumbra currently has a consensus target price of $304.45, indicating a potential upside of 50.73%. Globus Medical has a consensus target price of $66.33, indicating a potential upside of 30.73%. Given Penumbra's stronger consensus rating and higher probable upside, research analysts plainly believe Penumbra is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Globus Medical	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Do institutionals & insiders hold more shares of PEN or GMED?

88.9% of Penumbra shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 5.3% of Penumbra shares are held by insiders. Comparatively, 24.3% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to PEN or GMED?

In the previous week, Globus Medical had 2 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Globus Medical and 3 mentions for Penumbra. Penumbra's average media sentiment score of 1.30 beat Globus Medical's score of 0.71 indicating that Penumbra is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation and earnings, PEN or GMED?

Globus Medical has lower revenue, but higher earnings than Penumbra. Globus Medical is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.06B	7.38	$90.95M	$2.31	87.44
Globus Medical	$1.02B	6.73	$122.87M	$1.17	43.37

Which has more volatility and risk, PEN or GMED?

Penumbra has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Does the MarketBeat Community favor PEN or GMED?

Penumbra received 249 more outperform votes than Globus Medical when rated by MarketBeat users. Likewise, 80.47% of users gave Penumbra an outperform vote while only 67.83% of users gave Globus Medical an outperform vote.

Company	Underperform	Outperform
Penumbra	Outperform Votes 791 80.47%	Underperform Votes 192 19.53%
Globus Medical	Outperform Votes 542 67.83%	Underperform Votes 257 32.17%

Summary

Penumbra beats Globus Medical on 11 of the 18 factors compared between the two stocks.